KB Home (NYSE: KBH) fell 6% after quarterly EPS missed estimates, due in part to lower margin. The home builder also trimmed its full year margin forecas ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.

BioVie Inc. BIVI shares dropped 56% to $1.2399 after the company announced it raised $3 million through a secondary offering ...

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 0.07% to 42,156.22 while the NASDAQ rose 0.56% to 18,075.07. The S&P ...

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Wave Life Sciences Ltd.

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne ...

Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug ...